-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SMvhd2p8DCkL6sSvc9k9raxiqOq+UOPFpQcqf9lETGYqaTwSl50WuCpL6qTzMCuG CTaNaErc7vf930cn2R7AQw== 0000950153-02-001866.txt : 20021106 0000950153-02-001866.hdr.sgml : 20021106 20021106145931 ACCESSION NUMBER: 0000950153-02-001866 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20021106 ITEM INFORMATION: Financial statements and exhibits ITEM INFORMATION: FILED AS OF DATE: 20021106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIPID SCIENCES INC/ CENTRAL INDEX KEY: 0000071478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 430433090 STATE OF INCORPORATION: AZ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-00497 FILM NUMBER: 02811053 BUSINESS ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 BUSINESS PHONE: 925-249-4000 MAIL ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 FORMER COMPANY: FORMER CONFORMED NAME: NEW MEXICO & ARIZONA LAND CO DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: NZ CORP DATE OF NAME CHANGE: 20000810 8-K 1 p67206e8vk.htm 8-K e8vk
Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2002

LIPID SCIENCES, INC.

(Exact name of registrant as specified in its charter)
         
Delaware   0-497   43-0433090
 
 
(State or other
jurisdiction of
incorporation)		   (Commission File
Number) 		  (I.R.S Employer
Identification No.)
         
7068 Koll Center Parkway, Suite 401, Pleasanton, California       94566
     
(Address of principal executive offices)     (Zip Code)

Registrant’s telephone number, including area code:   (925) 249-4000

 

Item 7. Financial Statements and Exhibits
Item 9. Regulation FD Disclosure
SIGNATURE
EXHIBIT INDEX
EX-99.1

Table of Contents

Item 7. Financial Statements and Exhibits

         (c)  Exhibits

     
Exhibit   Description
 
99.1   Letter to Stockholders from the Chairman of the Board of Lipid Sciences, Inc.

Item 9. Regulation FD Disclosure

         On November 6, 2002, Lipid Sciences, Inc., a Delaware corporation, forwarded to its stockholders a letter from the Chairman of the Board. The letter is attached to this Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

 

Table of Contents

SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Lipid Sciences, Inc.
         
Date:  November 6, 2002   By:   /s/ Barry Michaels
       
    Name:
Title: 		  Barry Michaels
Chief Financial Officer

 

Table of Contents

EXHIBIT INDEX

     
Exhibit   Description
 
99.1   Letter to Stockholders from the Chairman of the Board of Lipid Sciences, Inc.

  EX-99.1 3 p67206exv99w1.htm EX-99.1 exv99w1

 

Exhibit 99.1

     
(Logo)   November 6, 2002

Dear Stockholder:

I wanted to take a moment to write to you about how things are proceeding at Lipid Sciences and to share with you the state of the corporation since I joined as your Chairman in September.

Change is a constant these days in business, and change for the better is what we are about at Lipid Sciences. Let me begin with the Board of Directors as an illustration. Just within the last four months, in addition to myself, two new members, Lew Meyer and H. Bryan Brewer, Jr., M.D., have joined us to provide a balance of business and science acumen. Through the Executive Committee we have been able to provide a resource to management while a national search for a Chief Executive Officer is conducted. This collective counsel will serve the stockholders well while work continues toward the commercialization of our novel technology of plasma delipidation.

The goal the Board of Directors has set for your corporation is to advance the science that we have at our disposal while prudently managing our costs and tailoring our activities to survive in a very uneven financing market. In order to maximize the assets (cash) we have at our disposal, your Board will be considering a variety of restructuring activities to improve operating efficiencies and set the stage for future growth. All activities are targeted to strengthen our focus of moving the science forward.

To that end, we will be pursuing a first indication for our viral platform specifically focused on HIV. HIV is a lipid-enveloped virus as are Hepatitis B and Hepatitis C and Herpes. We believe Lipid Sciences’ process may effectively inactivate the HIV particle and has the potential to be a therapeutic treatment for these diseases. Currently, in vitro and in vivo (animal) studies are being conducted in support of this indication. In addition, we are evaluating the preliminary results from our Phase 1 Human Safety Trial in Australia, which is currently paused, with the goal of advancing the science and improving the safety of the plasma delipidation process. We expect that this work could support both our viral and cardio-vascular technology platforms.

What we will seek to demonstrate to you over the coming months is the wise use of the existing assets to assure the future of your corporation. We recognize the need to reconfigure our infrastructure and operations, where appropriate, to meet the continuing challenges of a development-stage company and to strengthen the focus of moving the science toward commercialization. I will update you at regular intervals as we build awareness of Lipid Sciences’ technology in the marketplace as being revolutionary and as an attractive investment opportunity.

Thank you for your continuing interest and for your support.

Sincerely,

(Signature>

Richard G. Babbitt
Chairman of the Board

Forward-Looking Statements
This letter to stockholders contains forward-looking statements concerning plans, objectives, goals, strategies, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this letter to stockholders reflect our current beliefs and expectations on the date of this letter to stockholders. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers are referred to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: Our inability to obtain adequate funds, our inability to receive regulatory approval for or technology, which is only in the clinical development stage; delay or failure to complete clinical studies; our dependence on our license agreement with Aruba International; competition in our industry; failure to secure and enforce our intellectual property rights; our reliance on collaborations with strategic partners; risks associated with use of biological and hazardous materials; product liability claims; and economic downturn in the real estate market.

7068 Koll Center Parkway, Suite 401, Pleasanton, CA 94566-3111
Tel: 925-249-4000 Fax: 925-249-4040

  GRAPHIC 4 p67206p67206z0001.gif GRAPHIC begin 644 p67206p67206z0001.gif M1TE&.#EA[@!B`/<```````@("!`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`````[@!B```(_@"?"1Q(L*#!@P@3*ES(L*'# MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;- MFSASZMS)LZ?/GT"#"AU*M*C1HTB-CL*3Q,."IR66"&*5M*K5@:*H9%C@0()7 M"0XB+,B09M75LT4%>8C@P`(%"QDH9+@P@8*$!282H=WKLUF:"%XS9-#@H;"' M#(F:B"Q'D6BZAXL2* MUR=.#RRS&M^*>A18E$)^!U/RA! MQ1=GH'&&@DGX8,,8E9A"BBFGD/()*:2H,LR&.$8DB(<>M(<#$`B>`4<<;YQ! MA1)0./)B*:,D0)U9F^0P@OFD` M0@DL]`#D%VC8@4<<:'3!18M,GH+*GGL^2_F7`=$$F,>$8:9WQA""E-HI***K/0 M,DLMLZ1ZBHN^-.,J2K#*NM`H+8B@R$3D;C!)0[\.,&LF=B$6@@K8Q9?@%U20 M`0J,J%![K2VWV&)++;6HHBHJ@7YK4KBS(L0)&&"<^\R68*C1"B=,;%"!"&!P M4M##$1?4RB`M:-P"EA4`*ZQ`K:R`:0G7^1"?%$M$X0>T>E8+<"X\XX(+P:JD M]N.``( MB"D0)\/'_XSC`$"^OZWN*@@*B+J$44%>X&)@_K'3TY0X^!$//H,30<@!$S($OQ`:K@#V&\@H!@"L=?$/ M%$W7ESP5'LC12V(V+ZD%81I M`F"B[@CWQ"CNCHK%V]_6")<_I0ED`\`RY$`@@8.[L"4Z$EB#DR*H1I[I`F^O M.U632.$+.A;1C@2!7QZ?T43Y@9(@>3BA(%G8"N8!(`A?G)P7$8*'Q4AG,!F` M0?=*T2]5$`Q@`@-:[$B!"F1XLH.G%$@>;#5*$)H2``_H%2=<.3CD<2T(L"J` M\082!``J4B"`L$OGJ),9$M`!1GHZU;5J08N"P7&3O#@F,@,@@A;DP)XY_J@` M,_6H/][!J@**&,4H%+'"`4CLB@*9Q/P.\+M13*(%E5,90@!T-LN8P#K6J4$E M<"8M5*4J@Z2@Q2KZ)D^-5.VD*&WF'OT9K@,8(*(!J$+C!BD0-<"T``>@VO0. MT@HV%!(K&`"6B`!">@07;J4Q\;%&&CILC3*4"QAS!8P0IK>$0RO-74 MC=PS!W_%ISU;$(0,32*)).1CU#B1APHLP@7QA+CU;PHRA0@0I24`(2<#"#-NR+%(W0_L%='.``!G#%`VF@2E]=PCL" M?'9B%.G509JQ"43@P01G^P"!0D0%,S2K"TOX@0U.0`(A-`$P=9G+7":@G!+H M9;UO/[*)+Y1@`@UH0%DSP!H;O&E(WF`&*M!W!:BY'O9.H`(3<&8\ M9XO$04:AA@TDX+$*:($<`MP0.21@`WYL:BL28(`$Q#@CH@""]03CF:XPF%Y` M6`*)WI"&+LS7!B%(C>>$4YP'D6`\$3@!7P7B#.%9-5P)R`.+%3*\`&`-O+M[ MWD=:H6/\+G`SBT&,_@GJ-84N?$%!J[6!."USG>QL1T4L\'!<%B`(KL)T4@10 M'`$2^Q!$BA7,(7F#AS2P&>UYH`'3@9E[D[`$FK7U!(#Y,0NT0^DHM#7/AY'` M#["2OP(P01&<4(0<%%"Y!&R3(!<3J$$X404M\Q1X6Q:9F+4$O!O#&M>\WO5> M1.&!BH;`6*"C06!ZY![N>,<&+'ATI$F+!$Z]^4C2I6Y<,J#;9<**T"S+V'@% MHH@6T+C&+9"80*H@`A2\^AF'58`!:AR$=T]"!"*H`B=R0.,#N'O$8'"L`0Y0 M`37$.-XNC>R[)R8'@2-@`P9'RQFB4Q@5J`T(2`"""1;0N((3_G;` M@02"(&TAZL*RTH"OU1Y'`XO!S2H#L'">YH"**)7:0)@G@"U6P:O99-Q`Y`"K M$^?'@BL'``'J3DHSD*MFX2`+030CCVIB0`>X MFL)%E9C#"SQ`KQ](X0MIP(,=T$"%)#BH!!Y0CHB?,0BP'<#@N7Y&U5N*`)@R M02"_ZOE`F``V`U3@`50+@-!)>=(`#`#G`##`;Q41>0(@`.H(^"SCK?;XR$\= M>0,000XV`#5#7643W/UQO:C@A2^\60D7:``'V/"BN,*(:"\B12%D8(,0P0`\;%:V2"H&`!8[@Z1 M510(T8M^J"WAW/RM4'KFO_P,-5`Q`>=2!/D+>WYF&@_Z`5!`Y$)_51$)">0! M)`!D;^N(GH/`$.)`L)&)[1[8"(=`!BV$_DP!]4)5YDR>" M&R`R3+!-B;0`&62("NU(0,`@K3M,* M74:`>Y$(D,9>I/4F$D8G7;`%;Q,M2&4P010C%8@L4X!:\Z4B)Q!J)]`K6R(" M.151EH,UK0!(WS00*S@QAA,`#X`"+8`"<(@"(G@`7K)^"M`KB@`K")`A/I@\ M@3<_;QB'3=($)-@*WW8"M(S=3Q%AKHH`%X2@HKS*`70`HXX%)N`*0NQAE.438\UC_2H`!ZS M?@]0$+](/ZT@C+!R>`EQAO)(C_18/[L3<`8P`(HS.%71"L76=3CP`U&0A:B% MB7J""MNH1CXC,+`3.Z;@"35@'0_B89/J9RO1Y(O`F"$Y`"L["6MF(G\U>9,X"82JID^Q^,)IN]#/O9`IS,!Z? M$1<1,`%4(%P#A&4M4`5!4`%4(P!?QGFP<@!5,`F34`7Y4CA(@*#,`F#4%51(F<`[6<`-"\F(LP;$"?8!&OH0+NZ`ZPR`,OK`+/Y0^I$`(%L!=7M$` M)R`(4]8U2CF"`N`_`@$&F*

-ZSR"3RJ13!%``$24`AHF/^AB=ST1!Y!4!CMB)Y:#$*+-":&=`!:\)`?(!&LZ!&N_`+PV`,P_`+ M;I1)>V,*C4`"'J`!*B`%B1!X8"!_E8<`1O@,>>"DL,)TZD:AY/8U3[I%',J3 M_"A%*)"+4;-$OJBE87.(BV%Y$@!1[@`$^Q`",0@>I42;M@-_P)1$GE(D;3J^@A"HDP87$` M"*HPJZ=B.CZ#-S_D3GM#-$P%K1OR"^C42]P83!W9)U'"J^):&LPP"]V33NH$ M.][8E:>P0>WJ'\:`"IEH*A[%)]M2"L^:KS@R#/R:)WO3)R!U"IU$L%1B#/#Z M>W[B(JDP#`?JL!O"#,"@"C02?#2""KPP1!C+,A;A4$CA#,@`#'>SH\9`_E(C M.S'?5Q%YP*8O>Q*B\(P[<.`TMR M8%D*D;:2:W[/0+D.D0>9J[D2L[@-`0:))0=BBQ!,,&X*H0A"!P8UAQ!JD+L' M`5A5P`2QJY+KHK,68;@,<5BDA+JT$IFH!KB+H3H* GRAPHIC 5 p67206p67206z0002.gif GRAPHIC begin 644 p67206p67206z0002.gif M1TE&.#EA`0$5`/<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2 M4EI:6F-C8VMK:W-SX2$A(R,C)24E)RWN?GY^_O[_?W]_______________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M_____________________RP``````0$5```(_@`_"!Q(L*#!@P@3*ES(L*'# MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRH3)08.% M"C@MZ+1`H0*&F4"#"MWH04//"Q=\;O"`T$.%`1N&2IU*E:"'#!5Z4E@*44*! MJ%7#BG6)@8+9#!,[4&`0H@%"0\N/%Z)X<&!`QDN9-"P@4.'TQPV:,B0`8-K MUQ0!0P\ M,!AH-580000()$"``5(.F=61!-4*P0(0\*6>A3Q=Z*X%:JJI4[SP6H#!O/3N M1.!+-8D8&5-7W0E95K,-1!U"'$30T[@..#!F0H^.Y,$&K9$&<*(#B590!XY- MP&D#(&XET($:O!B!!!4(:6,#$CP -----END PRIVACY-ENHANCED MESSAGE-----